Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice-Reference-Cited by-同舟云学术

Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice

Published:2020-12 Issue: Volume:495 Page:112-122
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Smith Ross C.^ORCID,Bulanadi Jerikho C.,Gill Anthony J.,Rye Kerry-Anne,Hugh Thomas^ORCID,Proschogo Nicholas,Smith Sarah F.,Phillips Leo,Gong Xiaojuan,Julovi Sohel M.,Xue Aiqun,Moghaddam Minoo J.

Funder

The Cancer Surgery Research Foundation

Commonwealth Scientific and Industrial Research Organisation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Actual Incidence Data from 1982 to 2013 and Mortality Data from 1982 to 2014 with Projections to 2017 Cancer in Australia: an Overview, 2017. Cancer Series No. 78. Cat. No. CAN 75;Australian Institute of Health and Welfare,2017

2. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Canc. Res.,2014

3. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial;Goldstein;J. Natl. Cancer Inst.,2015

4. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen;Yoo;Oncotarget,2017

5. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N. Engl. J. Med.,2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches;Environmental Research;2024-01

2. Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy;Molecular Pharmaceutics;2022-11-21